GlassScriptPhysician profile
Janice Trinh
NPI 1760261507
$1,511.83
in general payments reported to CMS, 2019-2025
24 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $481 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $290.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $183.74 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $171.69 | 2024-2025 | Airsupra |
| Pfizer INC. | $98.62 | 2024-2025 | |
| Seqirus USA INC | $95.05 | 2024-2025 | Flucelvax, Fluad |
| Inspire Medical Systems, INC. | $85.76 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.06 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $50.57 | 2025 | Rexulti |
| Amgen INC. | $48.26 | 2025 | Krystexxa, Evenity |
| Hologic Sales and Service, LLC | $47.16 | 2024 | Aptima, Thinprep 2000 Processor |
| Edwards Lifesciences Corporation | $46.18 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Electromed, INC. | $44.01 | 2024-2025 | Smartvest |
| Medtronic, INC. | $43.96 | 2025 | Symplicity G3 |
| Astellas Pharma US INC | $41.57 | 2024-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $34.42 | 2025 | Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $22.35 | 2024 | |
| Abiomed | $21.48 | 2025 | |
| Ossur Americas, INC. | $21.27 | 2025 | |
| Glaxosmithkline, LLC. | $19.49 | 2025 | Shingrix, Bexsero |
| Cranial Technologies, INC | $19.36 | 2025 | Doc Band |
| Vertex Pharmaceuticals Incorporated | $19.06 | 2025 | |
| Abbvie INC. | $17.66 | 2025 | |
| Insulet Corporation | $15.01 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $14.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.